Jorge Darcourt, MD

Assistant Professor of Clinical Medicine in Oncology, Academic Institute
Assistant Clinical Member, Research Institute
Houston Methodist
Weill Cornell Medical College


Dr. Jorge Darcourt earned his medical degree at the Universidad de Buenos Aires in Argentina in 1999. He completed his residency at The University of Texas Health Science at Houston and his fellowship at Baylor College of Medicine in Hematology and Oncology. He currently serves as the medical director of the Methodist Sugar Land Infusion Center as well as chairman for the Department of Medicine. His personal goal is to bring cutting edge clinical trials and cancer treatments to the communities of the greater Houston area closer to the patients homes.

Description of Research

Dr. Darcourt's current research focuses on the study of the differential pathways of breast cancer metastasis to help us to understand the mechanisms of brain metastasis. The goal is to be able to identify and develop  more effective preventive and targeted therapies for this unmet need.  Dr. Darcourt is also interested in the modulation of the immune system for the prevention and treatment of cancer.

Areas Of Expertise

Breast cancer Immunotherapy Metastatic breast cancer GU cancer

Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases
Liu, ZB, Ezzedine, NE, Eterovic, AK, Ensor, Jr. JE, Huang, HJ, Albanell, J, Choi, DS, Lluch, A, Liu, Y, Rojo, F, Wong, H, Martínez-Dueñas, E, Guerrero-Zotano, Á, Shao, ZM, Darcourt, J, Mills, GB, Dave, B & Chang, JC 2019, Breast Cancer Research and Treatment, vol. 178, no. 2, pp. 251-261.

Short-term Mortality Associated with Definitive Chemoradiotherapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer
Haque, WM, Verma, V, Aghazadeh, M, Darcourt, J, Butler, EB & Teh, BS 2019, Clinical Genitourinary Cancer, vol. 17, no. 5, pp. e1069-e1079.

A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
Patel, T, Ensor, Jr. JE, Creamer, SL, Boone, T, Rodriguez, AA, Niravath, PA, Darcourt, J, Meisel, JL, Li, X, Zhao, J, Kuhn, JG, Rosato, RR, Qian, W, Belcheva, A, Schwartz, MR, Kaklamani, VG & Chang, JC 2019, Breast Cancer Research, vol. 21, no. 1, 100.

The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy
Shelburne, S, Darcourt, J, White, AC, Greenberg, SB, Hamill, RJ, Atmar, RL & Visnegarwala, F 2005, Clinical Infectious Diseases, vol. 40, no. 7, pp. 1049-1052.

Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy
Shelburne, S, Visnegarwala, F, Darcourt, J, Graviss, EA, Giordano, TP, White, AC & Hamill, RJ 2005, AIDS, vol. 19, no. 4, pp. 399-406.

Changes in metabolic profile among antiretroviral-naive patients initiating protease inhibitor versus non-protease inhibitor containing HAART regimens [3]
Visnegarwala, F, Darcourt, J, Sajja, P, Menon, V, Ong, O, Maldonado, M & White, AC 2003, Journal of Acquired Immune Deficiency Syndromes, vol. 33, no. 5, pp. 653-655.

Live Chat Available